|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-8-9
|
|
pubmed:abstractText |
Median survival times (STs) for doxorubicin-treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi-agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable level of toxicity. Thirty-two dogs with stage III-V multicentric lymphoma were treated with doxorubicin every 3 weeks for five total cycles and prednisone at a tapering dose for the first 4 weeks. Dogs were randomized to receive either cyclophosphamide or placebo concurrently. Seventeen dogs received doxorubicin and placebo, while 15 dogs received doxorubicin and cyclophosphamide. Response, toxicity, progression-free interval (PFI) and ST were evaluated. The combination of doxorubicin and cyclophosphamide was well tolerated, causing no increase in adverse events over doxorubicin alone. Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-10999761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-12092954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-12465768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-12762384,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-1289337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-1588546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-15892593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-1748977,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-18451250,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-19379294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-19417014,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-3721990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-8263847,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-856438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-893208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20691026-9040837
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1476-5829
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
188-95
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20691026-Animals,
pubmed-meshheading:20691026-Antibiotics, Antineoplastic,
pubmed-meshheading:20691026-Antineoplastic Agents, Alkylating,
pubmed-meshheading:20691026-Antineoplastic Agents, Hormonal,
pubmed-meshheading:20691026-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20691026-Cyclophosphamide,
pubmed-meshheading:20691026-Disease-Free Survival,
pubmed-meshheading:20691026-Dog Diseases,
pubmed-meshheading:20691026-Dogs,
pubmed-meshheading:20691026-Doxorubicin,
pubmed-meshheading:20691026-Female,
pubmed-meshheading:20691026-Lymphoma,
pubmed-meshheading:20691026-Male,
pubmed-meshheading:20691026-Neoplasm Staging,
pubmed-meshheading:20691026-Placebos,
pubmed-meshheading:20691026-Prednisone,
pubmed-meshheading:20691026-Prognosis,
pubmed-meshheading:20691026-Schools, Veterinary,
pubmed-meshheading:20691026-Survival Analysis,
pubmed-meshheading:20691026-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.
|
|
pubmed:affiliation |
Animal Cancer Center, Colorado State University College of Veterinary Medicine, Fort Collins, CO 80523-1620, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
